Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06329661 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
A Phase 4 study, sponsored by Novaliq.
- Completed
- Registry status
- Phase 4
- Development phase
- 204
- Enrollment target
NCT06329661 is a Phase 4 study that has completed, run by Novaliq. The registered enrollment target is 204 participants.
The verdict
NCT06329661, a Phase 4 study, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 204 participants
- Enrollment target
Study Summary
The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
Interventions
- DRUG Cyclosporine ophthalmic solution, 0.1%
- DRUG Saline solution, 0.6%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2025-07-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06329661
The ClinicalTrials.gov registry entry for NCT06329661 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novaliq, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclosporine ophthalmic solution, 0.1% is the first listed.
NCT06329661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06329661 about?
NCT06329661 is a clinical study titled "A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine". The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
What is the current status of trial NCT06329661?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 204 participants. The study started on 2024-04-22. Estimated completion is 2025-07-30.
What interventions are being tested in trial NCT06329661?
The interventions under investigation include: Cyclosporine ophthalmic solution, 0.1% (DRUG), Saline solution, 0.6% (DRUG).
Who is sponsoring clinical trial NCT06329661?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.